Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism | Zendy

Jelena Krstić | Zendy; Isabel Reinisch | Zendy; Katharina Schindlmaier | Zendy; Markus Galhuber | Zendy; Zina Riahi | Zendy; Natascha Berger | Zendy; Nadja Kupper | Zendy; Elisabeth Moyschewitz | Zendy; Martina Auer | Zendy; Helene Michenthaler | Zendy; Christoph Nössing | Zendy; Maria R. Depaoli | Zendy; Jeta RamadaniMuja | Zendy; Sinem Usluer | Zendy; Sarah Stryeck | Zendy; Martin Pichler | Zendy; Beate Rinner | Zendy; Alexander Deutsch | Zendy; Andreas Reinisch | Zendy; Tobias Madl | Zendy; Riccardo Zenezini Chiozzi | Zendy; Albert J. R. Heck | Zendy; Meritxell Huch | Zendy; Roland Malli | Zendy; Andreas Prokesch | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism

Author(s) -

Jelena Krstić,

Isabel Reinisch,

Katharina Schindlmaier,

Markus Galhuber,

Zina Riahi,

Natascha Berger,

Nadja Kupper,

Elisabeth Moyschewitz,

Martina Auer,

Helene Michenthaler,

Christoph Nössing,

Maria R. Depaoli,

Jeta RamadaniMuja,

Sinem Usluer,

Sarah Stryeck,

Martin Pichler,

Beate Rinner,

Alexander Deutsch,

Andreas Reinisch,

Tobias Madl,

Riccardo Zenezini Chiozzi,

Albert J. R. Heck,

Meritxell Huch,

Roland Malli,

Andreas Prokesch

Publication year - 2022

Publication title -

science advances

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.928

H-Index - 146

ISSN - 2375-2548

DOI - 10.1126/sciadv.abh2635

Subject(s) - sorafenib , hepatocellular carcinoma , cancer research , medicine , pi3k/akt/mtor pathway , protein kinase b , glycolysis , apoptosis , pharmacology , oncology , metabolism , biology , biochemistry

Cancer cells voraciously consume nutrients to support their growth, exposing metabolic vulnerabilities that can be therapeutically exploited. Here, we show in hepatocellular carcinoma (HCC) cells, xenografts, and patient-derived organoids that fasting improves sorafenib efficacy and acts synergistically to sensitize sorafenib-resistant HCC. Mechanistically, sorafenib acts noncanonically as an inhibitor of mitochondrial respiration, causing resistant cells to depend on glycolysis for survival. Fasting, through reduction in glucose and impeded AKT/mTOR signaling, prevents this Warburg shift. Regulating glucose transporter and proapoptotic protein expression, p53 is necessary and sufficient for the sorafenib-sensitizing effect of fasting. p53 is also crucial for fasting-mediated improvement of sorafenib efficacy in an orthotopic HCC mouse model. Together, our data suggest fasting and sorafenib as rational combination therapy for HCC with intact p53 signaling. As HCC therapy is currently severely limited by resistance, these results should instigate clinical studies aimed at improving therapy response in advanced-stage HCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research